Considering the clearly demonstrated results of in-vitro and in-vivo studies, an emphasizing pharmacological efficiency of BSTN1 against obesity and dyslipidemia is elucidated via PPAR-γ and AMPK modulation. The gene discussed is PPARG; the disease is obesity disorder.